April 28, 2022 06:15 AM EDTUpdated 08:50 AM

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout

Max Gelman

Senior Editor

Amber Tong

Novo Nordisk made waves early last year after showing that its blockbuster diabetes drug was also highly effective at treating non-diabetic adults with obesity. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout

Max Gelman

Senior Editor

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Are programs with compounded GLP-1s safe for your population?

Eli Lil­ly throws down the gaunt­let in obe­si­ty race, chal­leng­ing No­vo Nordisk with new PhI­II read­out

Senior Editor

Sign up to read this article for free.

Eli Lilly throws down the gauntlet in obesity race, challenging Novo Nordisk with new PhIII readout